Understanding the New Treatment Era of Alternative Therapies for Patients With Hemophilia A

Understanding the New Treatment Era of Alternative Therapies for Patients With Hemophilia A (May 2019)

Thursday, May 16, 2019
Webinar -- 2:00 PM ET


  • Current and emerging approaches to bleeding and prophylaxis
    • Pre-replacement therapy
    • Replacement therapy
    • Non-replacement therapy
    • Gene therapy
  • Overview of hemophilia treatment
  • Overcoming limitations of current therapies
  • Novel therapies
    • Extended half-life factors
    • Rebalancing the coagulation system
    • Factor VIII mimetics
    • Gene therapy
  • Incorporating patient and caregiver preferences when planning


Program Director
Guy A. Young, MD

Professor of Pediatrics
, Hemostasis and Thrombosis Center
Children's Hospital Los Angeles
University of Southern California Keck School of Medicine
Los Angeles, California

Michael Callaghan, MD

Associate Professor
Department of Hematology
Wayne State University
Division of Hematology/Oncology
Children's Hospital of Michigan
Detroit, Michigan

Miguel A. Escobar, MD

Professor of Medicine and Pediatrics
Department of Hematology
University of Texas Health Science Center
McGovern Medical School
Gulf States Hemophilia and Thrombophilia Center
Houston, Texas

Goal Statement
The goal of this activity is to improve participants’ competence in treating patients with hemophilia.

Target Audience
This program is intended for hematologists and other healthcare providers who care for patients with hemophilia.

Learning Objectives

  • Implement individualized hemophilia management strategies that optimize adherence, outcomes, and utilization of resources
  • Describe novel approaches to treating patients with hemophilia and inhibitors
  • Review the strengths and limitations of outcome measures used currently in hemophilia clinical practice/research and ongoing efforts to develop novel outcome measures that address these common limitations


Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.